Onder Tonyali1, Ugur Coskun2, Sinemis Yuksel3, Mevlude Inanc4, Oznur Bal5, Tulay Akman6, Dogan Yazilitas7, Arife Ulas8, Mehmet Kucukoner9, Asude Aksoy10, Umut Demirci11, Mukremin Uysal12, Ozgur Tanriverdi13, Yusuf Gunaydin2, Ahmet Taner Sumbul14, Ramazan Yildiz3, Halit Karaca4, Berna Oksuzoglu5, Aydin Ciltas2, Suleyman Buyukberber2, Mustafa Benekli2. 1. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Mustafa Kemal University, Hatay, Turkey. Electronic address: tonyalionder@yahoo.com. 2. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey. 3. Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey. 4. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Erciyes University, Kayseri, Turkey. 5. Department of Medical Oncology, Ankara Oncology Training and Research Hospital, Ankara, Turkey. 6. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey. 7. Department of Medical Oncology, Konya Numune Education and Research Hospital, Konya, Turkey. 8. Department of Medical Oncology, Ali Osman Sonmez Oncology Hospital, Bursa, Turkey. 9. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Dicle University, Diyarbakir, Turkey. 10. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Inonu University, Malatya, Turkey. 11. Department of Medical Oncology, Ankara Ataturk Education and Research Hospital, Ankara, Turkey. 12. Division of Medical Oncology, Department of Internal Medicine, Afyon Kocatepe University Faculty of Medicine, Afyonkarahisar, Turkey. 13. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Mugla University, Mugla, Turkey. 14. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Mustafa Kemal University, Hatay, Turkey.
Abstract
PURPOSE: The aim of this study was to determine risk factors for brain metastasis as the first site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who received adjuvant trastuzumab. METHODS: Medical records of 588 female patients who received 52-week adjuvant trastuzumab from 14 centers were evaluated. Cumulative incidence functions for brain metastasis as the first site of disease recurrence and the effect of covariates on brain metastasis were evaluated in a competing risk analysis and competing risks regression, respectively. RESULTS: Median follow-up time was 36 months. Cumulative incidence of brain metastasis at 12 months and 24 months was 0.6% and 2%, respectively. HER2-enriched subtype (ER- and PR-) tumor (p = 0.001, RR: 3.4, 95% CI: 1.33-8.71) and stage 3 disease (p = 0.0032, RR: 9.39, 95% CI: 1.33-8.71) were significant risk factors for development of brain metastasis as the first site of recurrence. CONCLUSIONS: In patients with HER2 positive EBC who received adjuvant trastuzumab, HER2-enriched subtype (ER- and PR-) tumor and stage 3 disease were associated with increased risk of brain metastasis as the first site of disease recurrence.
PURPOSE: The aim of this study was to determine risk factors for brain metastasis as the first site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who received adjuvant trastuzumab. METHODS: Medical records of 588 female patients who received 52-week adjuvant trastuzumab from 14 centers were evaluated. Cumulative incidence functions for brain metastasis as the first site of disease recurrence and the effect of covariates on brain metastasis were evaluated in a competing risk analysis and competing risks regression, respectively. RESULTS: Median follow-up time was 36 months. Cumulative incidence of brain metastasis at 12 months and 24 months was 0.6% and 2%, respectively. HER2-enriched subtype (ER- and PR-) tumor (p = 0.001, RR: 3.4, 95% CI: 1.33-8.71) and stage 3 disease (p = 0.0032, RR: 9.39, 95% CI: 1.33-8.71) were significant risk factors for development of brain metastasis as the first site of recurrence. CONCLUSIONS: In patients with HER2 positive EBC who received adjuvant trastuzumab, HER2-enriched subtype (ER- and PR-) tumor and stage 3 disease were associated with increased risk of brain metastasis as the first site of disease recurrence.
Authors: Christian Maurer; Lorraine Tulpin; Michel Moreau; Cristina Dumitrescu; Evandro de Azambuja; Marianne Paesmans; Jean-Marie Nogaret; Martine J Piccart; Ahmad Awada Journal: ESMO Open Date: 2018-10-24
Authors: Emanuela Ferraro; Jasmeet Singh; Sujata Patil; Pedram Razavi; Shanu Modi; Sarat Chandarlapaty; Andrea V Barrio; Rachna Malani; Ingo K Mellinghoff; Adrienne Boire; Hannah Y Wen; Edi Brogi; Andrew D Seidman; Larry Norton; Mark E Robson; Chau T Dang Journal: NPJ Breast Cancer Date: 2022-03-22
Authors: Dhiego Chaves de Almeida Bastos; Marcos Vinicius Calfat Maldaun; Raymond Sawaya; Dima Suki; Frederick F Lang; Paul D Brown; Ganesh Rao; Jeffrey S Weinberg; Sujit S Prabhu Journal: Neurooncol Pract Date: 2017-12-23